COGNITIVE-SYSTEMS
10.3.2021 11:02:12 CET | Business Wire | Press release
Cognitive Systems Corp. announced today an integration with Airties to offer its patented WiFi Motion technology across Airties’ portfolio of WiFi 6 solutions. Cognitive’s WiFi Motion will make it easier than ever for service providers to access this revolutionary sensing technology.
Over the past six years, Cognitive Systems has designed, developed, and implemented the first and most sophisticated WiFi-enabled motion sensing software on the market. WiFi Motion leverages connected IoT devices to turn the entire home into a motion-sensing network, introducing an innovative way to use WiFi. With 37 ISPs currently offering WiFi Motion around the globe, millions of homes already have access to this new service and its growing number of applications.
“Service providers are looking for new ways to differentiate from competitors and retain customers. Our priority is providing smart WiFi solutions that offer value beyond connectivity,” said Taj Manku, Co-Founder and CEO of Cognitive Systems. “Like us, Airties aims to shape the next generation of wireless solutions and see the possibilities for motion sensing, from smarter home monitoring to a higher standard of eldercare. We’re doing the legwork with their Wi-Fi 6 portfolio to get WiFi Motion ready for some forward-thinking Airties service providers who want to offer these benefits to their customers as soon as possible.”
Cognitive Systems and Airties share a commitment to staying ahead of the market, both by being active members of the Wireless Broadband Alliance (WBA) and closely following emerging trends. In addition to the current home monitoring capabilities, WiFi Motion’s highly anticipated eldercare solution will bring peace of mind to caregivers by providing discreet wellness monitoring without the need for cameras or wearable devices. The market for remote wellness monitoring products is growing rapidly. Soon customers will be able to receive notifications and gain valuable insights into not only their homes but also the homes of loved ones.
“As a pioneer and leader in Wi-Fi sensing, we are pleased to be working with Cognitive Systems on new Wi-Fi 6 solutions,” said Metin Taskin, Co-Founder and CTO of Airties. “Cognitive’s product roadmap has a realistic game plan for both implementation and longevity. The integration of WiFi Motion and Airties can enable service providers to offer innovative value-add Wi-Fi services to their customers.”
About Cognitive Systems
Cognitive Systems Corp. is on a mission to transform the way WiFi networks are used. Its flagship technology, WiFi Motion™, uses wireless signals to sense motion in the home. WiFi Motion harnesses artificial intelligence and predictive analytics to reliably identify and localize motion for the smart home, home monitoring, and wellness monitoring markets. This patented technology is layered onto existing WiFi networks without additional hardware to enhance service provider and router manufacturer offerings.
www.cognitivesystems.com
https://www.linkedin.com/company/cognitive-systems-corp-/
About Airties
Founded in 2004, Airties is the most widely deployed provider of managed in-home Wi-Fi solutions to operators around the globe. The company offers Smart Wi-Fi software, a cloud-based management platform, and Mesh extenders. Service providers turn to Airties for the design, implementation, and ongoing optimization of their customers’ broadband experience. With an installed base of over 30 million homes, Airties’ customers include: Altice USA, AT&T, Singtel, Sky, Telia, Telstra, and many others. More information is available at www.Airties.com
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210310005132/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom